서브메뉴
검색
Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras
Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202104742
- ISBN
- 9798290652276
- DDC
- 500
- 저자명
- Ahn, Green.
- 서명/저자
- Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras
- 발행사항
- [Sl] : Stanford University, 2023
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2023
- 형태사항
- 172 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 87-01, Section: B.
- 주기사항
- Advisor: Bertozzi, Carolyn.
- 학위논문주기
- Thesis (Ph.D.)--Stanford University, 2023.
- 초록/해제
- 요약Targeted protein degradation (TPD) is a promising strategy to remove deleterious proteins for therapeutic benefit and to probe biological pathways. The past two decades has witnessed a surge in development of technologies that rely on intracellular machinery to degrade challenging cytosolic targets. However, these TPD platforms leave the majority of extracellular and membrane proteins untouched. To enable degradation of these classes of proteins, we developed lysosome targeting chimeras (LYTACs) as a general strategy to degrade both secreted and membrane-anchored targets as introduced in Chapter 1.The first lysosome targeting chimeras (LYTACs) targeted extracellular and membrane proteins for degradation by bridging a target protein to the lysosome trafficking receptor, cation-independent mannose-6-phosphate receptor (CI-M6PR). Because CI-M6PR has broad tissue distribution, harnessing a receptor with tissue-restricted expression could mitigate off-target effects and allow tissue-specific degradation. In Chapter 2, we developed "GalNAc-LYTACs" that engage the asialoglycoprotein receptor (ASGPR), a liver-specific lysosomal targeting receptor, to degrade extracellular proteins in a cell type-specific manner. Site-specific conjugation and development of homogeneous LYTAC ligands improved the pharmacokinetic profile of GalNAc-LYTACs in vivo. GalNAc-LYTACs represent an avenue for cell-type restricted protein degradation, and additional discovery of recycling receptors with distinct and exclusive localization would expand the range of tissues or cells that LYTACs can target with selectivity. To address this need, we generated a comprehensive map of receptors that traffic from the plasma membrane to the lysosome across different tissues in mice in Chapter 3. Although extracellular degrader technologies have recently expanded the scope of potential therapeutic targets, no prior work has identified cellular features which enable or inhibit membrane protein degradation. Development of LYTACs as therapeutics would greatly benefit from insight into the factors that govern their activity. In Chapter 4, we conducted a genome-wide CRISPR screen to identify modulators of LYTAC-mediated membrane protein degradation. Our findings inform new design strategies for LYTACs with enhanced degradation activity and elucidate fundamental insights of receptor occupancy and trafficking.
- 일반주제명
- Plasma
- 일반주제명
- Glycoproteins
- 일반주제명
- Antibodies
- 일반주제명
- Biosynthesis
- 일반주제명
- Genomes
- 일반주제명
- Autophagy
- 일반주제명
- Biology
- 일반주제명
- Flow cytometry
- 일반주제명
- Liver cancer
- 일반주제명
- Cells
- 일반주제명
- CRISPR
- 일반주제명
- Recycling
- 일반주제명
- Medical research
- 일반주제명
- Pharmacokinetics
- 일반주제명
- Engineering
- 일반주제명
- Antigens
- 일반주제명
- Proteomics
- 기타저자
- Stanford University.
- 기본자료저록
- Dissertations Abstracts International. 87-01B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2023 us c eng d■001000017358723
■00520260202104742
■006m o d
■007cr#unu||||||||
■020 ▼a9798290652276
■035 ▼a(MiAaPQ)AAI32149719
■035 ▼a(MiAaPQ)Stanfordsd354ck8170
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a500
■1001 ▼aAhn, Green.
■24510▼aTargeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras
■260 ▼a[Sl]▼bStanford University▼c2023
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2023
■300 ▼a172 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 87-01, Section: B.
■500 ▼aAdvisor: Bertozzi, Carolyn.
■5021 ▼aThesis (Ph.D.)--Stanford University, 2023.
■520 ▼aTargeted protein degradation (TPD) is a promising strategy to remove deleterious proteins for therapeutic benefit and to probe biological pathways. The past two decades has witnessed a surge in development of technologies that rely on intracellular machinery to degrade challenging cytosolic targets. However, these TPD platforms leave the majority of extracellular and membrane proteins untouched. To enable degradation of these classes of proteins, we developed lysosome targeting chimeras (LYTACs) as a general strategy to degrade both secreted and membrane-anchored targets as introduced in Chapter 1.The first lysosome targeting chimeras (LYTACs) targeted extracellular and membrane proteins for degradation by bridging a target protein to the lysosome trafficking receptor, cation-independent mannose-6-phosphate receptor (CI-M6PR). Because CI-M6PR has broad tissue distribution, harnessing a receptor with tissue-restricted expression could mitigate off-target effects and allow tissue-specific degradation. In Chapter 2, we developed "GalNAc-LYTACs" that engage the asialoglycoprotein receptor (ASGPR), a liver-specific lysosomal targeting receptor, to degrade extracellular proteins in a cell type-specific manner. Site-specific conjugation and development of homogeneous LYTAC ligands improved the pharmacokinetic profile of GalNAc-LYTACs in vivo. GalNAc-LYTACs represent an avenue for cell-type restricted protein degradation, and additional discovery of recycling receptors with distinct and exclusive localization would expand the range of tissues or cells that LYTACs can target with selectivity. To address this need, we generated a comprehensive map of receptors that traffic from the plasma membrane to the lysosome across different tissues in mice in Chapter 3. Although extracellular degrader technologies have recently expanded the scope of potential therapeutic targets, no prior work has identified cellular features which enable or inhibit membrane protein degradation. Development of LYTACs as therapeutics would greatly benefit from insight into the factors that govern their activity. In Chapter 4, we conducted a genome-wide CRISPR screen to identify modulators of LYTAC-mediated membrane protein degradation. Our findings inform new design strategies for LYTACs with enhanced degradation activity and elucidate fundamental insights of receptor occupancy and trafficking.
■590 ▼aSchool code: 0212.
■650 4▼aPlasma
■650 4▼aGlycoproteins
■650 4▼aAntibodies
■650 4▼aBiosynthesis
■650 4▼aGenomes
■650 4▼aAutophagy
■650 4▼aBiology
■650 4▼aFlow cytometry
■650 4▼aLiver cancer
■650 4▼aCells
■650 4▼aCRISPR
■650 4▼aRecycling
■650 4▼aMedical research
■650 4▼aPharmacokinetics
■650 4▼aEngineering
■650 4▼aAntigens
■650 4▼aProteomics
■690 ▼a0306
■690 ▼a0537
■71020▼aStanford University.
■7730 ▼tDissertations Abstracts International▼g87-01B.
■790 ▼a0212
■791 ▼aPh.D.
■792 ▼a2023
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17358723▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.


